Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Treasury Shares (2020 - 2025)

Aclaris Therapeutics (ACRS) has 6 years of Treasury Shares data on record, last reported at $2.2 million in Q4 2025.

  • For Q4 2025, Treasury Shares rose 3.99% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $2.2 million, up 3.99%, while the annual FY2025 figure was $2.2 million, 3.99% up from the prior year.
  • Treasury Shares reached $2.2 million in Q4 2025 per ACRS's latest filing, down from $3.1 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $3.1 million in Q1 2024 and bottomed at $7313.0 in Q4 2021.
  • Average Treasury Shares over 5 years is $1.6 million, with a median of $1.6 million recorded in 2022.
  • Peak YoY movement for Treasury Shares: skyrocketed 21092.3% in 2022, then tumbled 97.77% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $7313.0 in 2021, then surged by 20694.89% to $1.5 million in 2022, then grew by 0.08% to $1.5 million in 2023, then soared by 37.73% to $2.1 million in 2024, then rose by 3.99% to $2.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $2.2 million in Q4 2025, $3.1 million in Q3 2025, and $69480.0 in Q2 2025.